Literature DB >> 7792757

HLA in familial and nonfamilial Mediterranean Kaposi's sarcoma in Greece.

A Kaloterakis1, C Papasteriades, A Filiotou, J Economidou, S Hadjiyannis, J Stratigos.   

Abstract

Fifty-four (54) unrelated patients with Mediterranean Kaposi's sarcoma (MKS) and 8 patients members of 4 unrelated families with familial MKS were serotyped for HLA-A,B and DR antigens. The diagnosis was histologically confirmed and all patients were negative for anti-HIV antibodies. An increased frequency of HLA-B18 (44.4% vs 14.2% in the controls, p < 0.001, RR = 4.8) and HLA-DR5 (57.6% vs 37.2% in the controls, p < 0.025, RR = 2.29) was observed in the group of patients with MKS. Seven (7) of the 8 family members with FMKS possessed HLA-DR5, and the affected members in the 3 families shared a common haplotype which included HLA-DR5. These findings support the hypothesis that genetic factors linked to HLA-DR5 antigen may contribute to the pathogenesis of MKS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7792757     DOI: 10.1111/j.1399-0039.1995.tb02427.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  12 in total

1.  Relationship between human leukocyte antigen alleles and risk of Kaposi's sarcoma in Cameroon.

Authors:  Elena M Cornejo Castro; Brian J Morrison; Vickie A Marshall; Nazzarena Labo; Wendell J Miley; Nathan Clements; George Nelson; Paul Ndom; Kristen Stolka; Jennifer J Hemingway-Foday; Mahamat Abassora; Xiaojiang Gao; Jennifer S Smith; Mary Carrington; Denise Whitby
Journal:  Genes Immun       Date:  2019-05-20       Impact factor: 2.676

2.  The expression profiles of microRNAs in Kaposi's sarcoma.

Authors:  Xiu-Juan Wu; Xiong-Ming Pu; Zong-Feng Zhao; Ya-Nan Zhao; Xiao-Jing Kang; Wei-Dong Wu; Yun-Min Zou; Cao-Ying Wu; Yuan-Yuan Qu; De-Zhi Zhang; Yan-Yan Feng; Jian-Yong Liu
Journal:  Tumour Biol       Date:  2014-10-01

Review 3.  Cutaneous lesions of the nose.

Authors:  Michael Sand; Daniel Sand; Christina Thrandorf; Volker Paech; Peter Altmeyer; Falk G Bechara
Journal:  Head Face Med       Date:  2010-06-04       Impact factor: 2.151

4.  Risk of Classic Kaposi Sarcoma With Combinations of Killer Immunoglobulin-Like Receptor and Human Leukocyte Antigen Loci: A Population-Based Case-control Study.

Authors:  James J Goedert; Maureen P Martin; Francesco Vitale; Carmela Lauria; Denise Whitby; Ying Qi; Xiaojiang Gao; Mary Carrington
Journal:  J Infect Dis       Date:  2015-08-12       Impact factor: 5.226

5.  Classic Kaposi's sarcoma in Morocco: clinico-epidemiological study at the National Institute of Oncology.

Authors:  Hassan Errihani; Narjisse Berrada; Soundouss Raissouni; Fadoi Rais; Hind Mrabti; Ghizlane Rais
Journal:  BMC Dermatol       Date:  2011-11-11

6.  Incidence of Kaposi Sarcoma in Sweden is Decreasing.

Authors:  Giedre Bieliauskiene; Oscar Zaar; Isabel Kolmodin; Martin Gillstedt; John Paoli
Journal:  Acta Derm Venereol       Date:  2020-10-28       Impact factor: 3.875

7.  MRI findings of AIDS-related giant facial Kaposi's sarcoma: A case report.

Authors:  Chun-Shuang Guan; Xue-Mei Wang; Zhi-Bin Lv; Shuo Yan; Lei Sun; Ru-Ming Xie
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

8.  Nationwide registry-based analysis of cancer clustering detects strong familial occurrence of Kaposi sarcoma.

Authors:  Eevi Kaasinen; Mervi Aavikko; Pia Vahteristo; Toni Patama; Yilong Li; Silva Saarinen; Outi Kilpivaara; Esa Pitkänen; Paul Knekt; Maarit Laaksonen; Miia Artama; Rainer Lehtonen; Lauri A Aaltonen; Eero Pukkala
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

9.  Familial Kaposi's Sarcoma: A Report of Five Cases from Greece.

Authors:  Kalliopi Armyra; Anargyros Kouris; Arsinoi Xanthinaki; Alexandros Stratigos; Irene Potouridou
Journal:  Case Rep Dermatol Med       Date:  2014-06-29

10.  MicroRNA-126-3p suppresses cell proliferation by targeting PIK3R2 in Kaposi's sarcoma cells.

Authors:  Xiu-Juan Wu; Zong-Feng Zhao; Xiao-Jing Kang; Hong-Juan Wang; Juan Zhao; Xiong-Ming Pu
Journal:  Oncotarget       Date:  2016-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.